Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

especially when it comes to certain modalities such as genetic medicine or cell or gene therapies. “We are bottom-up investors, so it's about owning a concentrated portfolio of these few special ...

At NYU Grossman School of Medicine, our commitment to innovation has led us to bold new ways of bridging the gap between basic science research, medical education, and quality of patient care. With ...